|
- 积分
- 85
- 威望
- 85
- 包包
- 41
|
1Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study 3 [" f( i& I: h+ K! v3 k5 x
http://circheartfailure.ahajournals.org/content/6/4/711.long) S, k2 \) {+ R$ \1 z! B+ a- O4 \
2，Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) http://circheartfailure.ahajournals.org/content/7/1/51.long
# \/ m$ i& k) u* U, c3，Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist.+ {5 w- P! p' [* M( |6 ~
http://www-ncbi-nlm-nih-gov.ezpr ... Receptor+Antagonist
0 w! P9 |. C0 E* G' Z$ ~, Z |
|
发表于 2014-5-28 23:30
发表于 2014-5-29 09:31
